Strongbridge Biopharma plc to Present at the Cowen and Company 38th Annual Healthcare Conference and the Oppenheimer 28th Ann...

Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Matthew Pauls, president and chief executive officer, will present at the Cowen and Company 38th Annual Healthcare Conference and the Oppenheimer 28th Annual Healthcare Conference.  The details of the conferences are as follows:

38th Annual Cowen and Company Healthcare Conference Tuesday, March 13 at 10:40 am ET The Boston Marriott Copley Place, Boston, MA

Oppenheimer 28th Annual Healthcare ConferenceWednesday, March 21 at 2:10 pm ET The Westin New York Grand Central, New York, NY

The Company’s presentations will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.

About Strongbridge Biopharma Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's commercial portfolio within its rare neuromuscular and rare endocrine franchises includes Keveyis®(dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, and Macrilen™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency. The Company’s rare endocrine franchise also includes a clinical-stage pipeline of therapies: Recorlev™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in other conditions amenable to somatostatin receptor activation.

Contacts:

Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco [phone] [e-mail]

Investor RelationsUnited States:The Trout Group Marcy Nanus [phone] [e-mail]

Europe:First HouseMitra Hagen Negård+47 21 04 62 [e-mail]

USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. [phone] Fax. [phone]